116 related articles for article (PubMed ID: 19297771)
1. Civil society strategy for the compulsory licensing of lopinavir/ritonavir: the Brazilian case.
Vieira MF; Reis R; Chaves G
HIV AIDS Policy Law Rev; 2008 Dec; 13(2-3):80-1. PubMed ID: 19297771
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacoeconomic aspects of lopinavir/ritonavir monotherapy].
Escobar Rodríguez I; Esteban Alba C
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 16():47-51. PubMed ID: 19572445
[TBL] [Abstract][Full Text] [Related]
3. Kaletra OK'd by FDA.
James JS
Posit Living; 2000 Nov; 9(9):8, 13. PubMed ID: 12154764
[No Abstract] [Full Text] [Related]
4. FDA notifications. Generic lopinavir/ritonavir approved by FDA.
AIDS Alert; 2009 May; 24(5):59. PubMed ID: 19452652
[No Abstract] [Full Text] [Related]
5. [Lopinavir/ritonavir monotherapy in the treatment of HIV infection. Introduction].
Pulido Ortega F; Arribas López JR
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 16():1. PubMed ID: 19572436
[No Abstract] [Full Text] [Related]
6. [Protease inhibitor Kaletra (Lopinavir/Ritonavir): significance and role in antiretroviral therapy of HIV infection and AIDS].
Galegov GA
Antibiot Khimioter; 2007; 52(1-2):42-5. PubMed ID: 18461809
[No Abstract] [Full Text] [Related]
7. [Kaletra (lopinavir/ritonavir--a new HIV protease inhibitor].
Ershov FI; Kas'ianova NV; Vasil'ev AN
Antibiot Khimioter; 2002; 47(11):27-9. PubMed ID: 12698577
[No Abstract] [Full Text] [Related]
8. Anti-HIV agents. Using only lopinavir/ritonavir (Kaletra).
TreatmentUpdate; 2008 Jan; 20(1):1-2. PubMed ID: 18320690
[No Abstract] [Full Text] [Related]
9. Lopinavir/ritonavir. (Kaletra).
Res Initiat Treat Action; 2000 Dec; 6(4):16-8. PubMed ID: 11708169
[No Abstract] [Full Text] [Related]
10. Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression.
Chan-Tack KM; Edozien A
J Acquir Immune Defic Syndr; 2006 Apr; 41(4):531-2. PubMed ID: 16652066
[No Abstract] [Full Text] [Related]
11. Anti-HIV agents. Lopinavir and ritonavir (Kaletra) tablets get tested.
TreatmentUpdate; 2008 Mar; 20(2):5-6. PubMed ID: 18661644
[No Abstract] [Full Text] [Related]
12. [Lopinavir/ritonavir monotherapy as a simplification strategy in the treatment of HIV-1 infection].
Pulido Ortega F; Llenas-García J
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 16():12-20. PubMed ID: 19572439
[TBL] [Abstract][Full Text] [Related]
13. [From research to clinical practice: use of lopinavir/ritonavir in monotherapy].
Valencia-Ortega ME; Moreno-Celda V
Enferm Infecc Microbiol Clin; 2008 Dec; 26(10):671-2. PubMed ID: 19100200
[No Abstract] [Full Text] [Related]
14. A king in the CASTLE? Optimum initial HIV protease inhibitor.
Torti C; Frank I
Lancet; 2008 Aug; 372(9639):604-6. PubMed ID: 18722849
[No Abstract] [Full Text] [Related]
15. Improving access to second-line antiretrovirals.
The Lancet
Lancet; 2007 Apr; 369(9570):1320. PubMed ID: 17448798
[No Abstract] [Full Text] [Related]
16. Lopinavir + ritonavir tablets: new formulation. More convenient, but minimal evaluation.
Prescrire Int; 2007 Aug; 16(90):148. PubMed ID: 17724839
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy.
Kempf DJ; Isaacson JD; King MS; Brun SC; Sylte J; Richards B; Bernstein B; Rode R; Sun E
Antivir Ther; 2002 Sep; 7(3):165-74. PubMed ID: 12487383
[TBL] [Abstract][Full Text] [Related]
18. Aluvia tablet approved in 19 African countries.
AIDS Patient Care STDS; 2007 Aug; 21(8):604-5. PubMed ID: 17902244
[No Abstract] [Full Text] [Related]
19. Focus on hepatitis. Low rate of liver problems seen with LPV/r.
Carter M
IAPAC Mon; 2005 Oct; 11(10):325. PubMed ID: 16673499
[No Abstract] [Full Text] [Related]
20. Kaletra approved in Canada.
TreatmentUpdate; 2001; 12(11):1-2. PubMed ID: 11570069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
